摘要
目的探究多巴丝肼联合吡贝地尔缓释片治疗帕金森病患者的临床疗效和安全性.方法将140例帕金森病患者按随机数字表法分为两组,每组70例,对照组予以多巴丝肼治疗,观察组予以多巴丝肼联合吡贝地尔缓释片治疗,观察6个月.采用帕金森氏病综合评分量表及Webster量表评估临床疗效,随时记录治疗过程中出现的不良反应,同时检测两组血清白细胞介素1β、胱抑素C水平变化.结果治疗后观察组总有效率(92.9%)显著高于对照组(80.0%)(P<0.05);帕金森氏病综合评分量表总分、各项目评分及Webster量表评分均显著低于对照组(P<0.01);血清白细胞介素1β、胱抑素C水平显著低于对照组(P<0.01);不良反应发生率(4.3%)显著低于对照组(17.1%)(P<0.05).结论多巴丝肼联合吡贝地尔缓释片治疗帕金森病具有协同增效作用,可改善患者病情,降低血清白细胞介素1β、胱抑素C水平,提高临床疗效,且安全性较高.
Objective To explore the clinical efficacy and safety of benserazide-levodopa combined with piribedil sustained-release tablets in the treatment of Parkinson's disease.Methods A total of 140 patients with PD were divided into two groups by the random number table method,each group has 70 cases.The control group was treated with benserazide-levodopa,and the observation group was treated with benserazide-levodopa combined with piribedil sustained-release tablets,patients were observed for 6 months.The clinical effects were evaluated by UPDRS and Webster scales,and the adverse reactions during the treatment were recorded at any time.The levels of serum interleukin-1 and cystatin C were also measured.Results After treatment,the total effective rate of treatment group(92.86%)was higher than that of the control group(80.00%)(P<0.05).UPDRS total score,project score and Webster scale score were significantly lower than those of the control group(P<0.01).Serum interleukin-13 and cystatin C levelswere significantly lower than those of the control group(P<0.01).The incidence of adverse reactions(4.3%)was significantly lower than that of the control group(17.1%)(P<0.05).Conclusion Benserazide-levodopa combined with piribedil sustained-release tablets in the treatment of Parkinson's disease has a synergistic effect,it can improve the patient's condition,reduce serum interleukin-1B,cystatin C levels,improve clinical efficacy,and with high safety.
作者
秦俊蕾
卢宏
吕慧敏
Qin Junlei;Lu Hong;Lv Huimin(First Affiliated Hospital of Zhengzhou University,Zhengzhou 450000,Henan,China)
出处
《临床心身疾病杂志》
CAS
2019年第2期51-55,共5页
Journal of Clinical Psychosomatic Diseases
基金
河南省高等学校重点科研计划项目(编号18A320052).
